123 related articles for article (PubMed ID: 24470239)
21. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma.
Pannem RR; Dorn C; Ahlqvist K; Bosserhoff AK; Hellerbrand C; Massoumi R
Carcinogenesis; 2014 Feb; 35(2):461-8. PubMed ID: 24104553
[TBL] [Abstract][Full Text] [Related]
22. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
23. Id1 is down-regulated by hepatocyte growth factor via ERK-dependent and ERK-independent signaling pathways, leading to increased expression of p16INK4a in hepatoma cells.
Ushio K; Hashimoto T; Kitamura N; Tanaka T
Mol Cancer Res; 2009 Jul; 7(7):1179-88. PubMed ID: 19567783
[TBL] [Abstract][Full Text] [Related]
24. Zanthoxylum avicennae extracts induce cell apoptosis through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells and block tumor growth in xenografted nude mice.
Dung TD; Chang HC; Chen CY; Peng WH; Tsai CH; Tsai FJ; Kuo WW; Chen LM; Huang CY
Int J Mol Med; 2011 Dec; 28(6):927-36. PubMed ID: 21874223
[TBL] [Abstract][Full Text] [Related]
25. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
26. ERK-dependent downregulation of Skp2 reduces Myc activity with HGF, leading to inhibition of cell proliferation through a decrease in Id1 expression.
Li X; Bian Y; Takizawa Y; Hashimoto T; Ikoma T; Tanaka J; Kitamura N; Inagaki Y; Komada M; Tanaka T
Mol Cancer Res; 2013 Nov; 11(11):1437-47. PubMed ID: 24177224
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Xia H; Ooi LL; Hui KM
Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
[TBL] [Abstract][Full Text] [Related]
28. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma.
Zhao J; Lu B; Xu H; Tong X; Wu G; Zhang X; Liang A; Cong W; Dai J; Wang H; Wu M; Guo Y
Hepatology; 2008 Jul; 48(1):265-75. PubMed ID: 18537194
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK).
Zhang S; Shan C; Kong G; Du Y; Ye L; Zhang X
Oncogene; 2012 Aug; 31(31):3607-20. PubMed ID: 22105365
[TBL] [Abstract][Full Text] [Related]
30. SRC signaling is crucial in the growth of synovial sarcoma cells.
Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
[TBL] [Abstract][Full Text] [Related]
31. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
32. RhoE is frequently down-regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho-kinase/myosin phosphatase target pathway.
Ma W; Wong CC; Tung EK; Wong CM; Ng IO
Hepatology; 2013 Jan; 57(1):152-61. PubMed ID: 22829315
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
34. Growth arrest and DNA damage 45G down-regulation contributes to Janus kinase/signal transducer and activator of transcription 3 activation and cellular senescence evasion in hepatocellular carcinoma.
Zhang L; Yang Z; Ma A; Qu Y; Xia S; Xu D; Ge C; Qiu B; Xia Q; Li J; Liu Y
Hepatology; 2014 Jan; 59(1):178-89. PubMed ID: 23897841
[TBL] [Abstract][Full Text] [Related]
35. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
36. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients.
Wang RY; Chen L; Chen HY; Hu L; Li L; Sun HY; Jiang F; Zhao J; Liu GM; Tang J; Chen CY; Yang YC; Chang YX; Liu H; Zhang J; Yang Y; Huang G; Shen F; Wu MC; Zhou WP; Wang HY
Gastroenterology; 2013 Dec; 145(6):1436-48.e1-12. PubMed ID: 23933603
[TBL] [Abstract][Full Text] [Related]
37. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-β.
Li HP; Zeng XC; Zhang B; Long JT; Zhou B; Tan GS; Zeng WX; Chen W; Yang JY
Carcinogenesis; 2013 Nov; 34(11):2443-51. PubMed ID: 23740840
[TBL] [Abstract][Full Text] [Related]
38. Altered regulation of Src tyrosine kinase by transforming growth factor beta1 in a human hepatoma cell line.
Fukuda K; Kawata S; Tamura S; Matsuda Y; Inui Y; Igura T; Inoue S; Kudara T; Matsuzawa Y
Hepatology; 1998 Sep; 28(3):796-804. PubMed ID: 9731575
[TBL] [Abstract][Full Text] [Related]
39. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis.
Trevino JG; Summy JM; Gray MJ; Nilsson MB; Lesslie DP; Baker CH; Gallick GE
Cancer Res; 2005 Aug; 65(16):7214-22. PubMed ID: 16103072
[TBL] [Abstract][Full Text] [Related]
40. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer.
Buck A; Buchholz M; Wagner M; Adler G; Gress T; Ellenrieder V
Mol Cancer Res; 2006 Nov; 4(11):861-72. PubMed ID: 17114344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
